Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 14 May 2018 – On 4 May 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 1 February 2018.

Under the programme initiated 4 May 2018, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 7 May 2018 to 6 August 2018.

Since the announcement as of 4 May 2018, the following transactions have been made under the programme:

<table>
<thead>
<tr>
<th>Date</th>
<th>Number of B shares</th>
<th>Average purchase price</th>
<th>Transaction value, DKK</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 May 2018</td>
<td>150,000</td>
<td>297.72</td>
<td>44,657,264</td>
</tr>
<tr>
<td>8 May 2018</td>
<td>145,000</td>
<td>300.84</td>
<td>43,621,086</td>
</tr>
<tr>
<td>9 May 2018</td>
<td>150,000</td>
<td>302.21</td>
<td>45,331,088</td>
</tr>
</tbody>
</table>

Accumulated under the programme: 445,000 B shares for a transaction value of 133,609,438 DKK.

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 25,188,093 B shares of DKK 0.20, corresponding to 1.0% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,450,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 1 February 2018. As of 9 May 2018, Novo Nordisk has
repurchased a total of 15,216,422 B shares at an average share price of DKK 303.96 per B share equal to a transaction value of DKK 4,625,160,777.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:
Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com

Investors:
Peter Hugreff Ankersen +45 3075 9085 phak@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Christina Kjær +45 3079 3009 cnje@novonordisk.com